Erythrocytes as Time Capsules of Disease Activity in Systemic Lupus Erythematosus
Erythrocytes as Time Capsules of Disease Activity in Systemic Lupus Erythematosus
批准号:
7253944
负责人:
Joseph M Ahearn
金额:
$28.16万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-07 至 2009-06-30
关键词:
AffectAgeAntigen-Antibody ComplexAutoantibodiesAutoimmune DiseasesBindingBiochemicalBiologicalBiological AssayBone MarrowChronicComplementComplement ActivationConditionDensity Gradient CentrifugationDepositionDetectionDevelopmentDiseaseDisease remissionDrug FormulationsErythrocytesFlareFlow CytometryFractionationGenetic PolymorphismGenotypeHandIndividualInflammationInflammatoryInvestigationLaboratoriesLongevityLupus ErythematosusMeasurementMediatingMolecularOrganPatientsPhenotypeProteinsResearchReticulocytesSurfaceSystemSystemic Lupus ErythematosusTestingTimeTissuesUrsidae Familyactivation productbasecapsuleclinically relevantdayin vivoinstrumentinterestnovel therapeutics
中文摘要
描述(由申请人提供):系统性红斑狼疮(SLE)是一种影响多器官的典型自身免疫性疾病。使用最近开发的流式细胞分析,我们发现在SLE患者的红细胞表面沉积了大量补体c4衍生的活化产物。初步研究中出现的其他有趣发现包括:1)在SLE患者中检测到红细胞结合的c4衍生激活产物(E-C4)水平升高和波动;2)同一患者中同时存在不同E-C4水平的不同红细胞亚群。这些发现导致了本研究的中心假设,即红细胞和网织红细胞可能分别充当SLE患者体内炎症状况(以及疾病活动性)的“时间胶囊”和“即时信使”。一方面,在疾病爆发期间循环的红细胞可能在其表面获得增加的c4衍生的活化产物,而从疾病爆发中出现的红细胞
英文摘要
DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease affecting multiple organs. Using a recently developed flow cytometric assay, we discovered the deposition of significant amounts of complement C4-derived activation product on the surface of erythrocytes of SLE patients. Additional interesting findings emerging from the preliminary studies include: 1) elevated and fluctuating levels of erythrocyte-bound C4-derived activation products (E-C4) were detected among SLE patients, and 2) distinct subpopulations of erythrocytes with different E-C4 levels were concurrently present in the same patient. These findings have led to the central hypothesis of this proposal that erythrocytes and reticulocytes may serve as, respectively, "time capsules" and "instant messenger" of the inflammatory condition in vivo (and thus disease activity) in SLE patients. On one hand, erythrocytes circulating during a disease flare may acquire an increased amount of C4-derived activation products on their surface, whereas erythrocytes emerging from the
bone marrow during remission may bear decreased levels of C4-derived products. On the other hand, reticulocytes (the youngest form of erythrocytes), when emerging from the bone marrow during an active disease state, may immediately be exposed to and acquire high levels of C4-derived products. Therefore, determination of the levels of C4-derived activation products on the surface of erythrocytes and reticulocytes circulating at any given time should reveal disease activity during the preceding 120 days (the life span of erythrocytes) and may provide clues to ongoing/forthcoming disease activation. The research proposed in this application is aimed to verify this hypothesis (Specifics Aim 1 and 2), to investigate the relationship between C4 polymorphism and the deposition of C4-derived products on erythrocytes/reticulocytes (Specific Aim 3), and to elucidate the biochemical basis of the deposition of C4-derived products on erythrocytes/reticulocytes (Specific Aim 4). The proposed studies will be accomplished by i) flow cytometric analysis of age-fractionated erythrocytes and reticulocytes, ii) statistical analysis of the correlation between E-C4 levels, reticulocyte-bound C4 levels, and SLE disease activity, iii) genotyping and phenotyping of C4 in SLE patients and healthy controls, and iv) biochemical studies of the interaction between erythrocytes and C4. These proposed studies will constitute the first endeavor aimed to investigate the biochemical and clinical relevance of the interaction between complement and erythrocytes/reticulocytes, in the context of SLE disease activity. Ultimately, information derived from the proposed studies may aid in the development of new laboratory tests for earlier and more accurate detection of SLE flares, and thereby facilitating the formulation and assessment of new therapeutic approaches for SLE.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.berh.2009.01.008
发表时间:
2009-08
期刊:
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
影响因子:
5.2
作者:
[Liu, Chau-Ching, Ahearn, Joseph M.]
通讯作者:
Ahearn, Joseph M.
Complement, Cardiovascular Disease, and SLE
-
批准号:6805641
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Erythrocytes as Time Capsules of Disease Activity in SLE
-
批准号:6772602
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Erythrocytes as Time Capsules of Disease Activity in SLE
-
批准号:7105057
-
项目类别:
-
资助金额:$29.0万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Erythrocytes as Time Capsules of Disease Activity in SLE
-
批准号:6924619
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Complement, Cardiovascular Disease, and SLE
-
批准号:6898927
-
项目类别:
-
资助金额:$34.81万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Complement, Cardiovascular Disease, and SLE
-
批准号:6733758
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Complement, Cardiovascular Disease, and SLE
-
批准号:7077805
-
项目类别:
-
资助金额:$29.76万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
Erythrocytes as Time Capsules of Disease Activity in SLE
-
批准号:6677400
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2003
-
负责人:Joseph M Ahearn
-
依托单位:
DAMAGE AND PATHOLOGIC FRACTURE IN VERTEBRAL BODIES
-
批准号:6232932
-
项目类别:
-
资助金额:$57.81万
-
财政年份:2001
-
负责人:Joseph M Ahearn
-
依托单位:
Rheumatic Diseases Core Center
-
批准号:6632786
-
项目类别:
-
资助金额:$57.39万
-
财政年份:2001
-
负责人:Joseph M Ahearn
-
依托单位:
Rheumatic Diseases Core Center
-
批准号:6732005
-
项目类别:
-
资助金额:$58.77万
-
财政年份:2001
-
负责人:Joseph M Ahearn
-
依托单位:
Rheumatic Diseases Core Center
-
批准号:6947774
-
项目类别:
-
资助金额:$48.13万
-
财政年份:2001
-
负责人:Joseph M Ahearn
-
依托单位:
Rheumatic Diseases Core Center
-
批准号:6512216
-
项目类别:
-
资助金额:$56.35万
-
财政年份:2001
-
负责人:Joseph M Ahearn
-
依托单位:
VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
-
批准号:6534497
-
项目类别:
-
资助金额:$26.25万
-
财政年份:1999
-
负责人:Joseph M Ahearn
-
依托单位:
VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
-
批准号:6082269
-
项目类别:
-
资助金额:$20.25万
-
财政年份:1999
-
负责人:Joseph M Ahearn
-
依托单位:
VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
-
批准号:6655100
-
项目类别:
-
资助金额:$26.25万
-
财政年份:1999
-
负责人:Joseph M Ahearn
-
依托单位:
VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
-
批准号:6315404
-
项目类别:
-
资助金额:$6.0万
-
财政年份:1999
-
负责人:Joseph M Ahearn
-
依托单位:
VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
-
批准号:6375300
-
项目类别:
-
资助金额:$26.25万
-
财政年份:1999
-
负责人:Joseph M Ahearn
-
依托单位:
VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
-
批准号:6171627
-
项目类别:
-
资助金额:$26.25万
-
财政年份:1999
-
负责人:Joseph M Ahearn
-
依托单位:
TARGETED IMMUNOGEN DELIVERY TO MURINE DENDRITIC CELLS
-
批准号:6099901
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1998
-
负责人:Joseph M Ahearn
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: